Intrahepatic Cholangiocarcinoma Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 18+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Intrahepatic Cholangiocarcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market.

Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report: https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Intrahepatic Cholangiocarcinoma Key players such as - Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment
• Intrahepatic Cholangiocarcinoma Emerging therapies such as - XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.
• In January 2024, Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company specializing in advanced personalized MRD technology (Haystack MRDTM), has partnered with TriSalus Life Sciences for a research collaboration. This initiative aims to assess therapeutic responses and gather molecular insights during the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. SD-101 is administered through hepatic arterial infusion or pancreatic retrograde venous infusion in Phase 1 and 1b trials using TriSalus' proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) system, designed to address intratumoral pressure challenges in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.

Intrahepatic Cholangiocarcinoma Overview
Intrahepatic cholangiocarcinoma (ICC) is a rare and aggressive form of cancer that originates in the bile ducts within the liver. These bile ducts are responsible for carrying bile, a digestive fluid, from the liver to the small intestine. ICC typically develops when abnormal cells in the bile ducts begin to grow uncontrollably, forming a tumor. The exact cause of ICC is not always clear, but risk factors include liver diseases like cirrhosis, chronic hepatitis B or C infections, and certain genetic conditions. Symptoms of ICC may include jaundice, abdominal pain, weight loss, and fatigue. The condition is often diagnosed through imaging tests, biopsy, and blood tests. Treatment options for ICC include surgery, chemotherapy, and targeted therapies, but the prognosis is generally poor, particularly in advanced stages.

Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Route of Administration
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment
• Intrahepatic Cholangiocarcinoma Assessment by Product Type
• Intrahepatic Cholangiocarcinoma By Stage and Product Type
• Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
• Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
• Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
• Intrahepatic Cholangiocarcinoma by Stage and Molecule Type

DelveInsight's Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Intrahepatic Cholangiocarcinoma Therapeutics Market include:
Key companies developing therapies for the Intrahepatic Cholangiocarcinoma are - Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array BioPharma, and others

Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Intrahepatic Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:
• XmAb®22841: Xencor, Inc.
• RLY-4008: Relay Therapeutics
• KIN-3248: Kinnate Biopharma
• FT-2102: Forma Therapeutics, Inc.
• SD 101: TriSalus Life Sciences
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
• VG161: Virogin Biotech Ltd
• Derazantinib: Basilea Pharmaceuticals

Intrahepatic Cholangiocarcinoma Pipeline Analysis:
The Intrahepatic Cholangiocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Intrahepatic Cholangiocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
• Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Intrahepatic Cholangiocarcinoma Pipeline Market Drivers
• Rising incidence of Cholangiocarcinoma. ICC makes up 8-10% of all Cholangiocarcinoma
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma Pipeline Market Barriers
• Poor prognosis and diagnosis of the disease
• Difficulty in developing novel therapies. Drugs may lose effectiveness after several months as the tumor may become resistant to the medication.

Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Intrahepatic Cholangiocarcinoma Companies: Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others
• Key Intrahepatic Cholangiocarcinoma Therapies: XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others
• Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
• Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.